Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Monoclonal Antibodies for Non-small Cell Lung Cancer market size was valued at US$ 12020 million in 2024 and is forecast to a readjusted size of USD 24920 million by 2031 with a CAGR of 10.9% during review period.

Non-Monoclonal Antibodies for Non-small Cell Lung Cancer are a class of biological agents targeting specific targets of non-small cell lung cancer (NSCLC), aiming to enhance the body's immune response by targeting specific antigens or immune checkpoints on the surface of cancer cells, thereby inhibiting tumor growth and metastasis. These monoclonal antibodies can be used to treat advanced or recurrent NSCLC, often in combination with chemotherapy or other immunotherapies, to increase treatment efficacy and improve patient survival.

This report is a detailed and comprehensive analysis for global Monoclonal Antibodies for Non-small Cell Lung Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Monoclonal Antibodies for Non-small Cell Lung Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Monoclonal Antibodies for Non-small Cell Lung Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Monoclonal Antibodies for Non-small Cell Lung Cancer

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Monoclonal Antibodies for Non-small Cell Lung Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche Holding AG, Bristol Myers Squibb Co., Elea Spa, Eli Lilly & Co., Merck & Co., Inc., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., Henlius Biopharma Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Innovent Biologics Co., Ltd, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Monoclonal Antibodies for Non-small Cell Lung Cancer market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

5 mg/mL

10 mg/mL

25 mg/mL

50 mg/mL

Market segment by Application

Hospitals

Clinic

Others

Major players covered

Roche Holding AG

Bristol Myers Squibb Co.

Elea Spa

Eli Lilly & Co.

Merck & Co., Inc.

AstraZeneca PLC

Regeneron Pharmaceuticals, Inc.

Henlius Biopharma Co., Ltd

Jiangsu Hengrui Medicine Co., Ltd

Innovent Biologics Co., Ltd

Junshi Biosciences Co., Ltd

BeiGene, Ltd

Akeso, Inc

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Monoclonal Antibodies for Non-small Cell Lung Cancer product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Monoclonal Antibodies for Non-small Cell Lung Cancer, with price, sales quantity, revenue, and global market share of Monoclonal Antibodies for Non-small Cell Lung Cancer from 2020 to 2025.

Chapter 3, the Monoclonal Antibodies for Non-small Cell Lung Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Monoclonal Antibodies for Non-small Cell Lung Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Monoclonal Antibodies for Non-small Cell Lung Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Monoclonal Antibodies for Non-small Cell Lung Cancer.

Chapter 14 and 15, to describe Monoclonal Antibodies for Non-small Cell Lung Cancer sales channel, distributors, customers, research findings and conclusion.